Insulin aspart (AT278) vs THDB0206

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline

Insulin aspart (AT278)

Developed by Arecor Limited

Phase 1 in Type 2 Diabetespeptide
Partial signal

NCT05754424 · Phase 1 · completed

Every participant received AT278 and the active comparator insulin in random order, with neither participants nor staff knowing which was given at each visit, which is a solid design. But the trial measured a pharmacology lab readout rather than a real-world blood sugar or complication outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Area under the glucose infusion rate-time curve of insulin aspart (0 to 60 minutes): Glucose clamp trial in overweight/obese people with Type 2 Diabetes (NCT05754424, AT278 U500 vs NovoRapid U100 vs Humulin R U500, 41 participants per EASD 2024 data matching registry enrollment): primary non-inferiority endpoint met with statistical superiority -- 1.7-fold higher glucose-lowering effect in first 60 min (95% CI 1.32-2.96, p<0.0001). (met)

Result source: NCT05754424

THDB0206

Developed by Adocia and partners

Phase 3 in Type 2 Diabetespeptide
Partial signal

NCT05834868 · Phase 3 · completed

The study was randomized and actively controlled with insulin lispro, but it was open-label and used change in HbA1c as its primary, surrogate endpoint rather than a hard clinical outcome. Registry results are not posted; the sponsors (Adocia and Tonghua Dongbao) announced positive topline results versus Humalog in July 2025, so the result rests on a company announcement.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

No aligned efficacy figure on record for this race.

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointInsulin aspart (AT278)THDB0206
HbA1c, change—Not reported—Not posted · NCT05834868
Body weight, change (kg)—Not reported—Not posted · NCT05834868
HbA1c below 7%—Not reported—Not posted · NCT05834868
Fasting plasma glucose, change—Not reported—Not posted · NCT05834868
3-point MACE (% with event)—Not reported—Not posted · NCT05834868

HbA1c, change

Insulin aspart (AT278)
—Not reported
THDB0206
—Not posted · NCT05834868

Body weight, change (kg)

Insulin aspart (AT278)
—Not reported
THDB0206
—Not posted · NCT05834868

HbA1c below 7%

Insulin aspart (AT278)
—Not reported
THDB0206
—Not posted · NCT05834868

Fasting plasma glucose, change

Insulin aspart (AT278)
—Not reported
THDB0206
—Not posted · NCT05834868

3-point MACE (% with event)

Insulin aspart (AT278)
—Not reported
THDB0206
—Not posted · NCT05834868
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

THDB0206: no structured comparison results are available for Type 2 Diabetes.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Insulin aspart (AT278)
Glucose clamp trial in overweight/obese people with Type 2 Diabetes (NCT05754424, AT278 U500 vs NovoRapid U100 vs Humulin R U500, 41 participants per EASD 2024 data matching registry enrollment): primary non-inferiority endpoint met with statistical superiority -- 1.7-fold higher glucose-lowering effect in first 60 min (95% CI 1.32-2.96, p<0.0001). NCT05754424 · Phase 1 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin aspart (AT278)'s landscape · THDB0206's landscape